sC5b-9 Antibody (Polyclonal - neoantigen)

A rabbit antiserum raised against human complement SC5b-9 protein.

250 µL

Highly purified human SC5b-9

Rabbit IgG

IgG Purified

The Anti-Human SC5b-9 Neoantigen IgG fraction is stringently absorbed with normal complement proteins to be monospecific for the SC5b-9 neoantigen. The purified IgG Fraction was tested by immunodiffusion and determined to be monospecific for the SC5b-9 neoantigen.

Short term (30 days) 4˚C. Long term at or below –20˚C.

Activation of the terminal complement pathway is the result of activation of any of the three pathways in the complement system: the classical, alternative and lectin pathways. In this process, complement protein C5 is cleaved to C5b and may then interact sequentially with complement proteins C6, C7, C8 and C9 forming the terminal complement complex (TCC). In the presence of a membrane, these complexes can form transmembrane pores causing complement mediated cytolysis. In the absence of a target membrane, the TCC binds to naturally occurring regulatory serum proteins and the resulting products are commonly called SC5b-9.